Logo-aim
Arch Iran Med. 2022;25(4): 250-256.
doi: 10.34172/aim.2022.41
  Abstract View: 93
  PDF Download: 74

Original Article

Immunohistochemical Overexpression of Cyclin D1 in Tunisian Invasive Breast Carcinoma Women

Lobna Bouzidi 1,2* ORCID logo, Saadia Makni 1,2, Jihen Feki 3, Rim Kallel 1,2, Soumaya Graja 1,2, Naourez Gouiaa 1,2, Tahya Sellami-Boudawara 1,2, Manel Mellouli 1,2

1 Department of Pathology and Research laboratory LR18SP10, University Hospital Habib Bourguiba, Sfax, Tunisia
2 Medical School of Sfax, University of Sfax, Sfax, Tunisia
3 Department of Medical Oncology, University Hospital Habib Bourguiba, Sfax, Tunisia
*Corresponding Author: Corresponding Author: Lobna Bouzidi, MD; Department of pathology Habib Bourguiba University Hospital. El Ain Road Km 0.5 3029. Sfax-Tunisia. Phone:+21644876050; E-mail: , Email: lobnalobna1992@gmail.com

Abstract

Background: Breast cancer represents the most frequent cancer and cause of death in women worldwide and in Tunisia. Cyclin D1 is a gene of cell cycle regulation. It represents a potential oncogene in invasive breast cancer; however; the results are conflicting. We performed a retrospective study aiming to analyze the prognostic impact of cyclin D1 expression in patients with invasive breast carcinoma of no special type and its relation with clinical-pathological features.

Methods: One hundred cases of invasive breast carcinoma of no special type diagnosed between 2009 and 2011 were included in this study. Immunohistochemical (IHC) staining was performed for cyclin D1 in all cases. Results were analyzed statistically.

Results: Cyclin D1 positivity was seen in 74 cases (74%), of which 32 cases (32%) showed strong immunoreactivity. Cyclin D1 staining was statistically significantly associated with estrogen receptor (ER) and progesterone receptor (PR) positivity (P<0.0001) and with low grade SBR (P=0.007). None of the clinical data and other pathological features had any association with cyclin D1 expression (P>0.05). Univariate analysis revealed that expression of cyclin D1 was not statistically associated with overall survival (OS) and disease-free survival (DFS) (P=0.459 and P=0.564, respectively).

Conclusion: These results confirm that cyclin D1 overexpression can be employed as a beneficial prognostic marker and suggest that anti-cyclin D1 therapy may be efficient, especially for ER positive tumors.


Cite this article as: Bouzidi L, Makni S, Feki J, Kallel R, Graja S, Gouiaa N, et al. Immunohistochemical overexpression of cyclin D1 in tunisian invasive breast carcinoma women. Arch Iran Med. 2022;25(4):250-256. doi: 10.34172/aim.2022.41
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 94

Your browser does not support the canvas element.


PDF Download: 74

Your browser does not support the canvas element.

Submitted: 03 Jan 2021
Revision: 03 Mar 2021
Accepted: 15 Mar 2021
ePublished: 01 Apr 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)